Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP insider Greg Keenan sold 12,239 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the sale, the insider now owns 161,789 shares of the company's stock, valued at approximately $1,294,312. This represents a 7.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Greg Keenan also recently made the following trade(s):
- On Friday, March 7th, Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock. The shares were sold at an average price of $8.23, for a total value of $68,350.15.
Aurinia Pharmaceuticals Stock Performance
Shares of NASDAQ:AUPH traded down $0.04 during trading on Friday, reaching $8.15. The company had a trading volume of 1,152,887 shares, compared to its average volume of 1,481,486. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -54.33 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock's fifty day moving average price is $8.08 and its 200 day moving average price is $7.87. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $27,000. Tower Research Capital LLC TRC grew its holdings in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $31,000. Finally, Natixis acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $49,000. Institutional investors and hedge funds own 36.83% of the company's stock.
Wall Street Analyst Weigh In
Separately, StockNews.com lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 19th.
Get Our Latest Stock Report on AUPH
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
